We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Microarray-Based Diagnostic Will Detect Sepsis-Triggering Pathogens

By Biotechdaily staff writers
Posted on 09 Oct 2007
A comprehensive DNA microarray-based diagnostic test will be able to detect both bacterial and fungal sepsis-triggering pathogens.

Approximately 18 million cases of sepsis occur worldwide per year. More...
The mortality rate for sepsis is 28-50%, and the associated costs are estimated at US$20 billion. Quick and precise diagnosis of sepsis is crucial to the success of a course of a therapy.

Current diagnostic processes rely on time-consuming cultivation of pathogenic microbes. The DNA microarray-based diagnostic under development will enable the immediate detection of organism-specific nucleic acid sequences, reduce the time between sample collection and diagnosis, and thus lead to a reduction in mortality rates.

GATC Biotech (Constance, Germany), a DNA sequencing service provider, has entered into a collaboration agreement with the Fraunhofer Institute in Germany, and the National University of Pusan (Pusan, Republic of Korea) and biotech company Gene In Corp., Ltd, (South Korea). GATC Biotech is the coordinating partner of the collaboration, which aims to develop the diagnostic test.

Peter Pohl, CEO of GATC Biotech, commented, "We are delighted to be taking part in this collaboration. With nearly two decades of experience in genetic analysis, GATC Biotech is ideally positioned to contribute to research projects relating to human health. The clinical diagnostics field is still dominated by classic microbial procedures, involving the time-consuming cultivation of pathogenic germs. The successful development of a DNA-based diagnostic will reduce the time between sample collection and diagnosis, and will represent a huge step towards increasing survival rates for patients.”

The project is one of several that connect GATC Biotech's DNA analysis expertise with demanding medical conditions. Additional projects that GATC Biotech is contributing to include CONSERT (Concerted Safety and Efficiency Evaluation of Retroviral Transgenesis for Gene Therapy of Inherited Diseases), XENOME (detection of retroviral elements in the porcine genome), and EURESFUN (integrated post-genomic approaches for the understanding, detection, and prevention of antifungal drug resistance in fungal pathogens).

GATC Biotech is a provider of DNA sequencing services and bioinformatics software for industry and academia worldwide. GATC Biotech offers complete sequencing systems, from sample prep to high-throughput genome sequencing and bioinformatics.


Related Links:
GATC Biotech
National University of Pusan

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.